An interventional study of Dual Focus Soft Contact Lens and Single Vision Soft Contact Lens in Myopia and Myopia Progression, sponsored by University of California, Berkeley. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by University of California, Berkeley · Not applicable, Interventional, and Treatment
Among 342 studies in Myopia with a site in United States — 27 open to participants now, 44 under way, 3 of them phase 3. Myopia · United States.
Among the 342 studies in Myopia with a site in United States, this one is the 75th largest by planned enrollment of the 294 interventional ones that give a count, is one of 18 that started in 2026, is one of 243 with no phase, reaches primary completion later than 42 of the 43 other live ones, and was the 334th registered.
1,159 studies on the registry are indexed under Myopia; 225 are open to participants now.
Browse Myopia studies →27 of the 342 studies in Myopia with a site in United States are open now. Recruiting first, the newest first:
CooperVision International Limited (CVIL) · Sites in United States
Ohio State University · Sites in United States
CooperVision International Limited (CVIL) · Sites in United States, Spain
Stanford University · Sites in United States
Jaeb Center for Health Research · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
342 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 15 · Phase 4 22
First in 1995; this study’s year is marked. 18 started in 2026.
This study's planned enrollment of 152 is above the median of 78 across 923 interventional studies indexed under Myopia.
Median enrollment 68 across the 294 interventional studies, 91 across the 46 observational. Of the 279 that completed or were terminated, 175 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
204 of 342 have an industry lead sponsor. The 10 most frequent:
University of California, Berkeley is the lead sponsor of 111 studies on the registry; 20 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of California, Berkeley has 3 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
13 of the studies in Myopia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06487897Phase 3VIS, Inc.Phase III Presbyopia Correction Using the VIS Opti-K™ System | 2026-12 |
| NCT06579287Sunhawk Vision Biotech, Inc.A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control | 2026-12 |
| NCT07751172CooperVision International Limited (CVIL)Evaluation of Orthokeratology Lenses With a 5MM Optic Zone Diameter | 2026-12 |
| NCT07679048Rochester Institute of TechnologyMeasuring How Quickly the Eye Focuses After Sustained Viewing of Close-up Images and Videos | 2026-12-15 |
| NCT05893979SightGlass Vision, Inc.Myopia Control Spectacle Lens Cessation Study | 2026-12-31 |
Among the 342 studies in Myopia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Myopia (nearsightedness) can continue to worsen during young adulthood, increasing the risk of sight-threatening eye diseases later in life. Although dual-focus soft contacts (DFSC) lenses have been shown to slow myopia progression in children, their effectiveness in adults is not well understood. This study will compare DFSC lenses with standard single-vision soft contact (SVSC) lenses in myopic young adults aged 18 to 30 years. Participants will be randomly assigned to wear one of the two lens types for 24 months. The study will measure changes in axial length and cycloplegic refractive error to determine whether DFSC lenses slow myopia progression in young adults.
This is a prospective, single-center, randomized, double-masked, parallel-group clinical trial designed to evaluate the efficacy of DFSC lenses for slowing myopia progression in young adults. Approximately 152 participants aged 18 to 30 years with documented ongoing myopia progression. will be randomized in a 1:1 ratio to wear either MiSight 1 day DFSC lenses or Proclear 1 day SVSC lenses for 24 months. The co-primary outcomes are changes in axial length and cycloplegic spherical equivalent refractive error over 24 months. Secondary outcomes include changes in choroidal parameters, including thickness, accommodation, and ocular safety. Outcome assessors will remain masked to treatment allocation throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Best-corrected distance visual acuity (BCDVA) in current correction as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will wear MiSight 1 day dual-focus soft contact lenses on a daily-wear basis for 24 months according to the study protocol.
Device: Dual Focus Soft Contact Lens
Participants will wear Proclear 1-day single-vision soft contact lenses on a daily wear basis for 24 months according to the study protocol.
Device: Single Vision Soft Contact Lens
MiSight 1 day is a daily disposable dual-focus soft contact lens with two treatment zones and two distance vision correction zones arranged in concentric rings.
Proclear 1 day is a daily disposable single-vision soft contact lens that provides conventional correction of refractive error without myopia control treatment zones.
Cycloplegic Spherical Equivalent Refraction
Change in cycloplegic spherical equivalent refraction (diopters) from baseline, measured by cycloplegic autorefraction after instillation of 1% tropicamide. Spherical equivalent will be calculated as sphere + one-half cylinder. The mean change from baseline will be compared between the DFSC and SVSC lens groups.
Time frame: Baseline, 12 months, and 24 months
Axial Length
Change in axial length (millimeters) from baseline. The mean change from baseline will be compared between two groups
Time frame: Baseline, 12 months, and 24 months
Acute Change in Choroidal Thickness
Change in subfoveal choroidal thickness (µm) measured using swept-source optical coherence tomography (SS-OCT) immediately before and after a 30-minute adaptation period while wearing the assigned contact lens.
Time frame: Baseline (pre-lens adaptation) and immediately following 30 minutes of contact lens wear (post-lens adaptation).
Quality of Vision
Change from baseline in quality of vision assessed using the Quality of Vision (QoV) Questionnaire, a previously validated patient-reported outcome measure comprising three Rasch-scaled subscales (Frequency, Severity, and Bothersome), each ranging from 0 to 100, with higher scores indicating worse quality of vision. Subscale scores will be compared between treatment groups at the prespecified study visits.
Time frame: Baseline, 2 weeks, 12 months, and 24 months
Accommodative Response
Change from baseline in dynamic accommodative response (diopters) measured objectively over a range of accommodative demands using the Shack-Hartmann aberrometer. Responses will be compared between treatment groups.
Time frame: Baseline, 2 weeks, 6 months, 12 months, and 24 months
Ocular Safety
Cumulative incidence of ocular and contact lens-related adverse events occurring from baseline through 12 months and from baseline through 24 months will be compared between treatment groups.
Time frame: Baseline through 12 months and Baseline through 24 months
Longitudinal Change in Choroidal Thickness
Change in subfoveal choroidal thickness (µm) measured using swept-source optical coherence tomography (SS-OCT) over the study period to evaluate the longitudinal effect of the assigned contact lens.
Time frame: Baseline, 6 months, 12 months and 24 months
Choroidal vascularity index (CVI)
Change from baseline in choroidal vascularity index (CVI), measured using swept-source optical coherence tomography (SS-OCT), to evaluate longitudinal changes during contact lens treatment.
Time frame: Baseline, 6 months, 12 months, and 24 months.
Plan to share: Yes — De-identified individual participant data that underlie the results reported in publications arising from this study will be made available. Data will be shared only after all direct identifiers have been removed and reasonable measures have been taken to minimize the risk of participant re-identification. Data sharing will be conducted in accordance with applicable institutional policies, participant consent, and regulatory requirements to protect participant confidentiality. De-identified individual participant data will be shared as CSV files.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will become available beginning 6 months after publication of the primary study results and will remain available for up to 7 years after publication.
Access criteria: De-identified data will be made available to qualified researchers for scientifically sound research purposes. Investigators requesting access must submit a methodologically appropriate research proposal describing the intended use of the data. Requests will be reviewed by the study investigators, and access may require approval by the University of California, Berkeley, execution of a data use agreement, and compliance with applicable institutional and regulatory requirements. Data will be provided only for purposes consistent with the informed consent provided by study participants.
Start is estimated for Sep 2026; primary completion for Sep 2030, 48 months later.
Of 200 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 48 months is above that.
Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Berkeley →